Form 4 for HRMY Harmony Biosciences Holdings, Inc.
Accepted 2025-01-28 00:00:00 ET · period of report 2025-01-24 · accession 0001415889-25-002160 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-28 | 2025-01-24 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | M - OptEx | $25.47 | +15.8K | 2,687 | New | +$402.8K |
| DM | 2025-01-28 | 2025-01-24+ | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | S - Sale+OE | $37.38 | -14.8K | 0 | -100% | -$551.5K |
| D | 2025-01-28 | 2025-01-24 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | F - Tax | $38.01 | -1,058 | 1,629 | -39% | -$40.2K |
| DM | 2025-01-28 | 2025-01-24 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | M - OptEx | $0.00 | -15.8K | 8,063 | -66% | $0 |
| DM | 2025-01-28 | 2025-01-25 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | A - Grant | $0.00 | +60.6K | 47.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-24 | M | A | 13,125 | $30.69 | 13,125 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-24 | S | D | 8,000 | $36.94 | 5,125 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-01-27 | S | D | 1,629 | $38.02 | 0 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.40. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-01-24 | M | A | 2,687 | $0.00 | 2,687 | D | — | — | |
| 5 | Common | Common Stock | 2025-01-24 | F | D | 1,058 | $38.01 | 1,629 | D | — | — | (F4) Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| 6 | Common | Common Stock | 2025-01-24 | S | D | 5,125 | $37.87 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.485 to $38.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Stock Option | 2025-01-24 | M | D | 13,125 | $0.00 | 39,375 | D | $30.69 · — to 2034-01-24 | 13,125 Common Stock | (F6) The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| 8 | Derivative | Restricted Stock Units | 2025-01-25 | A | A | 13,450 | $0.00 | 13,450 | D | — · — to — | 13,450 Common Stock | (F9) The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. (F8) The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| 9 | Derivative | Stock Option | 2025-01-25 | A | A | 47,200 | $0.00 | 47,200 | D | $38.01 · — to 2035-01-25 | 47,200 Common Stock | (F8) The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| 10 | Derivative | Restricted Stock Units | 2025-01-24 | M | D | 2,687 | $0.00 | 8,063 | D | — · — to — | 2,687 Common Stock | (F7) This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |